C3i’s expertise in the clinical, pharmacovigilance, and pharma sales support domains and strong partnership with industry leading products in these respective areas will enable HCLTech’s life sciences customers to become more patient-centric and offer services to IT and business stakeholders to improve healthcare outcomes.
C3i Solutions Aquisition
Drug Safety &
We have the Process, the People and the Technology needed to deliver high quality, scalable, product safety solutions to meet your needs.
The features and functions that should be top of mind when reviewing technologies to support your patient engagement program
Patient Engagement Tech
The Experience Matters
HCLTech, a global technology company, acquired C3i Solutions, a multi-channel customer engagement services provider specializing in global, high-touch consumer, patient and end-user management in 2018. With this acquisition, HCLTech is helping its life sciences customers become more patient-centric and develop solutions to address the digital revolution happening within the industry. Powered by a global team of 222,000+ diverse and passionate people across 60 countries, HCLTech deliver smarter, better ways for all our stakeholders to benefit from technology. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG and Public Services.
Clinical Trials & REMS in the Time of Corona: FDA & MHRA Advice and Guidance
Pharmacovigilance expert Bart Cobert discusses the FDA and MHRA guidance for non-Corona related clinical trials.
Does Rapid FDA Approval Produce Drug Safety Issues?
Bart Cobert gives his pharmacovigilance point of view on a recent paper on FDA approval timelines and drug safety issues.
Bart Cobert on the importance of publishing clinical trials data and implications on pharmacovigilance.
This is an interesting article looking at what PV will be in the year 2030.
FDA Draft Guidance on PMRs
Bart Cobert highlights the most important changes in the recently revised FDA draft guidance on PMRs.
Ranitidine – What Happened and What Do We Learn?
Bart Cobert explores several important points to take from the still ongoing signal and safety issue with Renitidine recall.
Going Mobile: Creating Experiences that Matter with the Avaya Mobile Experience
Read how C3i Solutions is leveraging Avaya Mobile Experience to provide better customer experience.
Vaping – A Serious Safety Signal
Bart Cobert discusses the major safety issue in the US on e-cigarettes and vaping.
Importing Canadian Drugs to the US
Bart Cobert covers several issues involved in setting up the proposed "Safe Importation Plan" which aims to allow US consumers to get safe and cheaper drugs.
No-No's in Drug Safety
An overview covering a number of things to avoid doing when it comes to drug safety.
Artificial Intelligence & Automation
Drug Safety & Pharmacovigilance